The DOI matches its Crossref record; 232 of the 232 references it cites were found in a registry or an index.
Nanopreparations to overcome multidrug resistance in cancer
Open accessAbstract
Multidrug resistance is the most widely exploited phenomenon by which cancer eludes chemotherapy. Broad variety of factors, ranging from the cellular ones, such as over-expression of efflux transporters, defective apoptotic machineries, and altered molecular targets, to the physiological factors such as higher interstitial fluid pressure, low extracellular pH, and formation of irregular tumor vasculature are responsible for multidrug resistance. A combination of various undesirable factors associated with biological surroundings together with poor solubility and instability of many potential therapeutic small & large molecules within the biological systems and systemic toxicity of chemotherapeutic agents has necessitated the need for nano-preparations to optimize drug delivery. The physiology of solid tumors presents numerous challenges for successful therapy. However, it also offers unique opportunities for the use of nanotechnology. Nanoparticles, up to 400 nm in size, have shown great promise for carrying, protecting and delivering potential therapeutic molecules with diverse physiological properties. In this review, various factors responsible for the MDR and the use of nanotechnology to overcome the MDR, the use of spheroid culture as well as the current technique of producing micro tumor tissues in vitro are discussed in detail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics
Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,725
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
ABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662 · cited 1×
“The pathogenesis of tumor hypoxia is well explained by Vaupel et al [74, 75].”
BackgroundMechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 3×
“Tumors are characteristically heterogeneous in terms of their hypoxic regions but they usually form a hypoxic/necrotic core and an outer shell of rapidly proliferating cells [61].”
BackgroundThe unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,748
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
Multicellular tumor spheroids: An underestimated tool is catching up again
Hirschhaeuser, F., Menne, H., Dittfeld, C., West, J., Mueller-Klieser, W., & Kunz-Schughart, L. A. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.01.012 · Cited by 1,674
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Wykoff, C. C., Beasley, N. J. P., Watson, P. H., Turner, K., Pastorek, J., Sibtain, A., Wilson, G. D., Turley, H., Talks, K., Maxwell, P. H., et al. (2000) · PubMed · Cited by 1,491
Determinants of tumor blood flow: a review.
Jain, R. K. (1988) · PubMed · Cited by 1,379
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
TORCHILIN, V (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.009 · Cited by 1,273
Self-citationOncogenic alterations of metabolism
Dang, C. V., & Semenza, G. L. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01344-9 · Cited by 1,106
Reed, J. C. (1998) · Oncogene · doi:10.1038/sj.onc.1202591 · Cited by 1,049
TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENT
Tlsty, T. D., & Coussens, L. M. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100224 · Cited by 987
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Recent progress in tumor pH targeting nanotechnology
Lee, E. S., Gao, Z., & Bae, Y. H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.003 · Cited by 866
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857
Wang, F., Wang, Y.-C., Dou, S., Xiong, M.-H., Sun, T.-M., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn200007z · Cited by 813
Targeted pharmaceutical nanocarriers for cancer therapy and imaging
Torchilin, V. P. (2007) · The AAPS Journal · doi:10.1208/aapsj0902015 · Cited by 762
Self-citationSethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R., et al. (1999) · Nature Medicine · doi:10.1038/9511 · Cited by 739
Hurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., & Kabbinavar, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 688
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
Chen, A. M., Zhang, M., Wei, D., Stueber, D., Taratula, O., Minko, T., & He, H. (2009) · Small · doi:10.1002/smll.200900621 · Cited by 671
Lord, R. V., Brabender, J., Gandara, D. R., Alberola, V., Camps, C., Dómine, M., Cardenal, F., Sánchez, J. M., Gumerlock, P. H., Tarón, M., et al. (2002) · PubMed · Cited by 668
Zhang, X., Lin, Y., & Gillies, R. J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.068981 · Cited by 659
Crystal structure of the ATP-binding subunit of an ABC transporter
Hung, L.-W., Wang, I. X., Nikaido, K., Liu, P.-Q., Ames, G. F.-L., & Kim, S.-H. (1998) · Nature · doi:10.1038/25393 · Cited by 656
Tumor microenvironment: The role of the tumor stroma in cancer
Li, H., Fan, X., & Houghton, J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21159 · Cited by 646
Grant, C. E., Valdimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P. C., & Deeley, R. G. (1994) · PubMed · Cited by 627
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor
Lee, E. S., Na, K., & Bae, Y. H. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.12.018 · Cited by 577
Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment
Wojtkowiak, J. W., Verduzco, D., Schramm, K. J., & Gillies, R. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200292c · Cited by 566
Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies
Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., & Toomey, D. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00003-3 · Cited by 559
“SMART” Drug Delivery Systems: Double-Targeted pH-Responsive Pharmaceutical Nanocarriers
Sawant, R. M., Hurley, J. P., Salmaso, S., Kale, A., Tolcheva, E., Levchenko, T. S., & Torchilin, V. P. (2006) · Bioconjugate Chemistry · doi:10.1021/bc060080h · Cited by 540
Self-citationLitman, T., Brangi, M., Hudson, E., Fetsch, P., Abati, A., Ross, D. D., Miyake, K., Resau, J. H., & Bates, S. E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.2011 · Cited by 538
Recent advances in apoptosis, mitochondria and drug resistance in cancer cells
Indran, I. R., Tufo, G., Pervaiz, S., & Brenner, C. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.03.010 · Cited by 526
Schneider, E. (1998) · FEMS Microbiology Reviews · doi:10.1016/s0168-6445(98)00002-3 · Cited by 514
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
Ganta, S., & Amiji, M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800240j · Cited by 490
Role of hypoxia in the hallmarks of human cancer
Ruan, K., Song, G., & Ouyang, G. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22214 · Cited by 489
Cancer and the tumor microenvironment: a review of an essential relationship
Mbeunkui, F., & Johann, D. J. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0881-9 · Cited by 487
Transcription-independent pro-apoptotic functions of p53
Moll, U. M., Wolff, S., Speidel, D., & Deppert, W. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.007 · Cited by 468
Lu, C., Altieri, D. C., & Tanigawa, N. (1998) · PubMed · Cited by 459
Cahill, D. P., Levine, K. K., Betensky, R. A., Codd, P. J., Romany, C. A., Reavie, L. B., Batchelor, T. T., Futreal, P. A., Stratton, M. R., Curry, W. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2149 · Cited by 452
Poly(l-histidine)–PEG block copolymer micelles and pH-induced destabilization
Lee, E. S., Shin, H. J., Na, K., & Bae, Y. H. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00205-0 · Cited by 451
cRGD‐Functionalized Polymer Micelles for Targeted Doxorubicin Delivery
Nasongkla, N., Shuai, X., Ai, H., Weinberg, B. D., Pink, J., Boothman, D. A., & Gao, J. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200460800 · Cited by 434
23 Genetic instability induced by the tumor microenvironment
Glazer, P. M., Reynolds, T. Y., & Rockwell, S. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)80581-0 · Cited by 427
Taxol: Mechanisms of Action and Resistancea
HORWITZ, S. B., LOTHSTEIN, L., MANFREDI, J. J., MELLADO, W., PARNESS, J., ROY, S. N., SCHIFF, P. B., SORBARA, L., & ZEHEB, R. (1986) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1986.tb38455.x · Cited by 416
An overview of cancer multidrug resistance: a still unsolved problem
Lage, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8111-5 · Cited by 408
Multi-functional nanocarriers to overcome tumor drug resistance
Jabr-Milane, L. S., van Vlerken, L. E., Yadav, S., & Amiji, M. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.04.003 · Cited by 407
Sun, T.-M., Du, J.-Z., Yao, Y.-D., Mao, C.-Q., Dou, S., Huang, S.-Y., Zhang, P.-Z., Leong, K. W., Song, E.-W., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn103349h · Cited by 406
Juweid, M. E., Neumann, R. D., Paik, C. H., Pérez-Bacete, M., Sato, J., van Osdol, W. W., & Weinstein, J. N. (1992) · PubMed · Cited by 406
ABCG2: determining its relevance in clinical drug resistance
Robey, R. W., Polgar, O., Deeken, J., To, K. W., & Bates, S. E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9042-6 · Cited by 387
Oxygen, a source of life and stress
Brahimi-Horn, M. C., & Pouysségur, J. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.06.018 · Cited by 383
Cairns, R., Papandreou, I., & Denko, N. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0002 · Cited by 370
Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer
Saad, M., Garbuzenko, O. B., & Minko, T. (2008) · Nanomedicine · doi:10.2217/17435889.3.6.761 · Cited by 367
Evaluation of HIF-1 inhibitors as anticancer agents
Semenza, G. L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.006 · Cited by 363
Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics
Gerweck, L. E., Vijayappa, S., & Kozin, S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0024 · Cited by 362
Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W., & Park, T. G. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.03.008 · Cited by 362
(2001) · PubMed · Cited by 350
Layer-by-Layer Nanoparticles with a pH-Sheddable Layer for in Vivo Targeting of Tumor Hypoxia
Poon, Z., Chang, D., Zhao, X., & Hammond, P. T. (2011) · ACS Nano · doi:10.1021/nn200876f · Cited by 343
Dantzig, A. H., Shepard, R. L., Cao, J., Law, K. L., Ehlhardt, W. J., Baughman, T. M., Bumol, T. F., & Starling, J. J. (1996) · PubMed · Cited by 328
Houghton, P. J., Germain, G. S., Harwood, F. C., Schuetz, J. D., Stewart, C. F., Buchdunger, E., & Traxler, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3344 · Cited by 323
Breedveld, P., Beijnen, J. H., & Schellens, J. H. M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.009 · Cited by 323
Patil, Y., Sadhukha, T., Ma, L., & Panyam, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.01.021 · Cited by 317
Nanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
Tumor hypoxia and cancer progression
Zhou, J., Schmid, T., Schnitzer, S., & Brüne, B. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.05.028 · Cited by 302
Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F. W., Wong, F., Blumenschein, G., Fleming, D. R., et al. (2005) · Cancer · doi:10.1002/cncr.21227 · Cited by 302
le Coutre, P., Ottmann, O. G., Giles, F., Kim, D.-W., Cortes, J., Gattermann, N., Apperley, J. F., Larson, R. A., Abruzzese, E., O'Brien, S. G., et al. (2008) · Blood · doi:10.1182/blood-2007-04-083196 · Cited by 294
PEG conjugated VEGF siRNA for anti-angiogenic gene therapy
Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W., & Park, T. G. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.023 · Cited by 273
Weber, C. E., & Kuo, P. C. (2012) · Surgical Oncology · doi:10.1016/j.suronc.2011.09.001 · Cited by 271
Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells
Shi, Q., Le, X., Wang, B., Abbruzzese, J. L., Xiong, Q., He, Y., & Xie, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204500 · Cited by 259
Song, X., Liu, X., Chi, W., Liu, Y., Wei, L., Wang, X., & Yu, J. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0224-7 · Cited by 258
Stimulus-responsive nanopreparations for tumor targeting
Zhu, L., & Torchilin, V. P. (2013) · Integrative Biology · doi:10.1039/c2ib20135f · Cited by 258
Self-citationTumor tissue oxygenation as evaluated by computerized-po2-histography
Kallinowski, F., Zander, R., Hoeckel, M., & Vaupel, P. (1990) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(90)90018-f · Cited by 253
Filleur, S., Courtin, A., Ait‐Si‐Ali, S., Guglielmi, J., Arnold, C., Harel‐Bellan, A., Clézardin, P., & Cabon, F. (2003) · PubMed · Cited by 253
(1992) · PubMed · Cited by 252
Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.
Volk, E. L., Farley, K. M., Wu, Y. F., Li, F., Robey, R. W., & Schneider, E. (2002) · PubMed · Cited by 248
(1992) · PubMed · Cited by 247
Multistage pH‐Responsive Liposomes for Mitochondrial‐Targeted Anticancer Drug Delivery
Mo, R., Sun, Q., Xue, J., Li, N., Li, W., Zhang, C., & Ping, Q. (2012) · Advanced Materials · doi:10.1002/adma.201201498 · Cited by 244
Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs
Shin, H.-C., Alani, A. W. G., Rao, D. A., Rockich, N. C., & Kwon, G. S. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.024 · Cited by 243
The Crystal Structure of the MJ0796 ATP-binding Cassette
Yuan, Y.-R., Blecker, S., Martsinkevich, O., Millen, L., Thomas, P. J., & Hunt, J. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100758200 · Cited by 243
Bae, S., Ma, K., Kim, T. H., Lee, E. S., Oh, K. T., Park, E.-S., Lee, K. C., & Youn, Y. S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.050 · Cited by 236
An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Takara, K., Sakaeda, T., & Okumura, K. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775201965 · Cited by 236
Abolhoda, A., Wilson, A. E., Ross, H., Danenberg, P. V., BURT, M. E., & Scotto, K. W. (1999) · PubMed · Cited by 231
Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting
Perche, F., & Torchilin, V. P. (2013) · Journal of Drug Delivery · doi:10.1155/2013/705265 · Cited by 230
Self-citationKale, A. A., & Torchilin, V. P. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060228x · Cited by 228
Self-citationThe P-glycoprotein multidrug transporter
Fardel, O., Lecureur, V., & Guillouzo, A. (1996) · General Pharmacology: The Vascular System · doi:10.1016/s0306-3623(96)00081-x · Cited by 223
Taxol: mechanisms of action and resistance.
Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Hj, S., & Yang, C.-P. (1993) · PubMed · Cited by 221
Xu, L., Pirollo, K. F., Tang, W.-H., Rait, A., & Chang, E. H. (1999) · Human Gene Therapy · doi:10.1089/10430349950016357 · Cited by 218
van Vlerken, L. E., Duan, Z., Seiden, M. V., & Amiji, M. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1648 · Cited by 214
Huang, S., Shao, K., Liu, Y., Kuang, Y., Li, J., An, S., Guo, Y., Ma, H., & Jiang, C. (2013) · ACS Nano · doi:10.1021/nn400548g · Cited by 212
Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Mahon, F.-X., Hayette, S., Lagarde, V., Belloc, F., Turcq, B., Nicolini, F., Belanger, C., Manley, P. W., Leroy, C., Etienne, G., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1008 · Cited by 212
Song, X. R., Cai, Z., Zheng, Y., He, G., Cui, F. Y., Gong, D. Q., Hou, S. X., Xiong, S. J., Lei, X. J., & Wei, Y. Q. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.02.018 · Cited by 211
Koch, C. J. (2002) · Methods in Enzymology · doi:10.1016/s0076-6879(02)52003-6 · Cited by 207
Wong, H. L., Bendayan, R., Rauth, A. M., & Wu, X. Y. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.09.007 · Cited by 207
Allen, J. D., Brinkhuis, R. F., van Deemter, L., Wijnholds, J., & Schinkel, A. H. (2000) · PubMed · Cited by 200
Koukourakis, M. I., Giatromanolaki, A. N., Sivridis, E., Simopoulos, K., Pastorek, J., Wykoff, C. C., Gatter, K. C., & Harris, A. L. (2001) · PubMed · Cited by 200
Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine
Yokoi, K., & Fidler, I. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0488 · Cited by 199
Survivin splice variants regulate the balance between proliferation and cell death
Caldas, H., Jiang, Y., Holloway, M. P., Fangusaro, J., Mahotka, C., Conway, E. M., & Altura, R. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208350 · Cited by 199
Williams, A. C., Collard, T. J., & Paraskeva, C. (1999) · Oncogene · doi:10.1038/sj.onc.1202660 · Cited by 196
pH and drug resistance in tumors
Raghunand, N., & Gillies, R. J. (2000) · Drug Resistance Updates · doi:10.1054/drup.2000.0119 · Cited by 194
Schmitt‐Sody, M., Strieth, S., Krasnici, S., Sauer, B., Schulze, B. G., Teifel, M., Michaelis, U., Naujoks, K., & Dellian, M. (2003) · PubMed · Cited by 192
Ajabnoor, G. M. A., Crook, T., & Coley, H. M. (2012) · Cell Death & Disease · doi:10.1038/cddis.2011.139 · Cited by 189
Problems of Delivery of Monoclonal Antibodies: Pharmaceutical and Pharmacokinetic Solutions
Reilly, R. M., Sandhu, J., Alvarez-Diez, T. M., Gallinger, S., Kirsh, J., & Stern, H. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528020-00004 · Cited by 187
Cheng, D., Cao, N., Chen, J., Yu, X., & Shuai, X. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.057 · Cited by 184
Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Safa, A., Day, T., & Wu, C.-H. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908783497087 · Cited by 184
Li, J., Wang, Y., Zhao, M., Tan, C., Li, Y., Le, X., Ji, L., & Mao, Z. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.12.035 · Cited by 182
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Nooter, K., Westerman, A. M., Flens, M. J., Zaman, G. J., Scheper, R. J., van Wingerden, K. E., Burger, H., Oostrum, R. G., Boersma, T., & Sonneveld, P. (1995) · PubMed · Cited by 174
Patel, N. R., Rathi, A., Mongayt, D., & Torchilin, V. P. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.082 · Cited by 173
Self-citationAnticancer Efficacies of Cisplatin-Releasing pH-Responsive Nanoparticles
Xu, P., Van Kirk, E. A., Murdoch, W. J., Zhan, Y., Isaak, D. D., Radosz, M., & Shen, Y. (2006) · Biomacromolecules · doi:10.1021/bm050902y · Cited by 171
Navarro, G., Sawant, R. R., Biswas, S., Essex, S., Tros de Ilarduya, C., & Torchilin, V. P. (2012) · Nanomedicine · doi:10.2217/nnm.11.93 · Cited by 170
Self-citationBindra, R. S., & Glazer, P. M. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.03.013 · Cited by 168
(1993) · PubMed · Cited by 166
Susa, M., Iyer, A. K., Ryu, K., Hornicek, F. J., Mankin, H., Amiji, M. M., & Duan, Z. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-399 · Cited by 164
Milosevic, M., Fyles, A., Hedley, D., & Hill, R. (2004) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2004.04.006 · Cited by 163
Differential subcellular localization of functionally divergent survivin splice variants
Mahotka, C., Liebmann, J., Wenzel, M., et al. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401091 · Cited by 162
Milane, L., Duan, Z., & Amiji, M. (2011) · Molecular Pharmaceutics · doi:10.1021/mp1002653 · Cited by 161
Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice
Wang, J., Chen, C., Li, B., Yu, H., Zhao, Y., Sun, J., Li, Y., Xing, G., Yuan, H., Tang, J., et al. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.001 · Cited by 160
Lhommé, C., Joly, F., Walker, J. L., Lissoni, A. A., Nicoletto, M. O., Manikhas, G. M., Baekelandt, M. M. O., Gordon, A. N., Fracasso, P. M., Mietlowski, W. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9807 · Cited by 158
Microvascular studies on the origins of perfusion-limited hypoxia.
Dewhirst, M. W., Kimura, H., Rehmus, W., Braun, R. D., Papahadjopoulos, D., Hong, K., & Secomb, T. W. (1996) · Europe PMC (PubMed Central) · Cited by 157
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan
Vukovic, V., & Tannock, I. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.201 · Cited by 156
Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance
Cuvier, C., Roblot-Treupel, L., Millot, J. M., Lizard, G., Chevillard, S., Manfait, M., Couvreur, P., & Poupon, M. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90443-m · Cited by 156
TUMOUR CELL PROLIFERATION IN RELATION TO THE VASCULATURE
Hirst, D. G., & Denekamp, J. (1979) · Cell Proliferation · doi:10.1111/j.1365-2184.1979.tb00111.x · Cited by 154
Hypoxia and anemia: effects on tumor biology and treatment resistance
Vaupel, P. W., & Mayer, A. (2005) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2004.11.005 · Cited by 153
Perche, F., Patel, N. R., & Torchilin, V. P. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.003 · Cited by 149
Self-citationTumor Physiology and Drug Resistance
Tannock, I. F. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013125027697 · Cited by 147
Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P. R., Villalona, M. A., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L. A., Kraynak, M. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2964 · Cited by 146
Berns, A. J. M. (2005) · Nature · doi:10.1038/436787a · Cited by 146
Shen, J., Yin, Q., Chen, L., Zhang, Z., & Li, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.08.007 · Cited by 143
Kunstfeld, R., Wickenhauser, G., Michaelis, U., Teifel, M., Umek, W. H., Naujoks, K., Wolff, K. S., & Petzelbauer, P. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12057.x · Cited by 139
Krieg, A. H., Mahotka, C., Krieg, T. M., Grabsch, H. I., Müller, W., Takeno, S., Suschek, C. V., Heydthausen, M., Gabbert, H. E., & Gerharz, C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600153 · Cited by 138
Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells
Choi, S. H. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.07.011 · Cited by 136
Nakagawa, M., Schneider, E., Dixon, K. H., Horton, J., Kelley, K., Morrow, C., & Cowan, K. H. (1992) · PubMed · Cited by 136
Lee, C. M., Tanaka, T. T., Murai, T., Kondo, M., Kimura, J., Su, W., Kitagawa, T., Ito, T., Matsuda, H., & Miyasaka, M. (2002) · PubMed · Cited by 132
Involvement of the DNA mismatch repair system in antineoplastic drug resistance
Lage, H., & Dietel, M. (1999) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050258 · Cited by 130
Takagi, A., Watanabe, M., Ishii, Y., Morita, J., HIROKAWA, Y. S., Matsuzaki, T., & Shiraishi, T. (2007) · PubMed · Cited by 129
Prabha, S., & Labhasetwar, V. D. (2004) · Molecular Pharmaceutics · doi:10.1021/mp049970+ · Cited by 128
Apoptotic Pathways and Therapy Resistance in Human Malignancies
Viktorsson, K., Lewensohn, R., & Zhivotovsky, B. (2005) · Advances in cancer research · doi:10.1016/s0065-230x(05)94004-9 · Cited by 126
Wang, X.-L., Xu, R., Wu, X., Gillespie, D. L., Jensen, R. L., & Lu, Z. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800192d · Cited by 125
Hyeon, L. S., Kim, S. H., & Park, T. G. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.185 · Cited by 125
Surface‐Modified LPD Nanoparticles for Tumor Targeting
Li, S., & Huang, L. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1348.001 · Cited by 123
Tumor targeting and microenvironment-responsive nanoparticles for gene delivery
Huang, S., Shao, K., Kuang, Y., Liu, Y., Li, J., An, S., Guo, Y., Ma, H., He, X., & Jiang, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.043 · Cited by 123
Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice
Murata, N., Takashima, Y., Toyoshima, K., Yamamoto, M., & Okada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.11.017 · Cited by 122
Devalapally, H., Duan, Z., Seiden, M. V., & Amiji, M. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4973 · Cited by 121
Ford, J. M., Bruggemann, E. P., Pastan, I. H., Gottesman, M. M., & Hait, W. N. (1990) · PubMed · Cited by 121
Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells
de Verdière, A. C., Dubernet, C., Némati, F., Poupon, M., Puisieux, F., & Couvreur, P. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686509 · Cited by 119
Bartholomeusz, G. A., Cherukuri, P., Kingston, J., Cognet, L., Lemos, R., Leeuw, T. K., Gumbiner-Russo, L., Weisman, R. B., & Powis, G. (2009) · Nano Research · doi:10.1007/s12274-009-9026-7 · Cited by 119
Hypoxia, drug therapy and toxicity
Lee, K., Roth, R. A., & LaPres, J. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.001 · Cited by 119
Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery
Sawant, R. R., Sriraman, S. K., Navarro, G., Biswas, S., Dalvi, R. A., & Torchilin, V. P. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.11.088 · Cited by 119
Self-citationHu, Q., Li, W., Hu, X.-R., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.060 · Cited by 119
Yin, J., Lao, F., Meng, J., Fu, P. P., Zhao, Y., Xing, G., Gao, X., Sun, B., Wang, P. C., Chen, C., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.048348 · Cited by 119
Shuhendler, A. J., Cheung, R. Y., Manias, J. L., Connor, A., Rauth, A. M., & Wu, X. Y. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0271-3 · Cited by 118
Shain, K. H., & Dalton, W. S. (2001) · PubMed · Cited by 117
Li, W., & Melton, D. W. (2011) · Oncogene · doi:10.1038/onc.2011.426 · Cited by 116
Liu, X., Xiong, M., Shu, X., Tang, R.-Z., & Wang, J. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300193f · Cited by 113
Devalapally, H., Duan, Z., Seiden, M. V., & Amiji, M. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22886 · Cited by 110
Antiangiogenic Targeting Liposomes Increase Therapeutic Efficacy for Solid Tumors
Chang, D.-K., Chiu, C., Kuo, S.-Y., Lin, W.-C., Lo, A., Wang, Y., Li, P., & Wu, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900280200 · Cited by 109
Lila, A. S. A., Kizuki, S., Doi, Y., Suzuki, T., Ishida, T., & Kiwada, H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.02.023 · Cited by 107
Defects of the apoptotic pathway as therapeutic target against cancer
Mashima, T., & Tsuruo, T. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.11.001 · Cited by 106
Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery
Tailor, T. D., Hanna, G., Yarmolenko, P., Dreher, M. R., Warner, A. B., Nixon, A. B., Spasojević, I., & Dewhirst, M. W. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0856 · Cited by 106
Ross, D., Wooten, P., Sridhara, R. N., Ordóñez, J. V., Lee, E., & Schiffer, C. (1993) · Blood · doi:10.1182/blood.v82.4.1288.1288 · Cited by 105
Strieth, S., Eichhorn, M., Sauer, B., Schulze, B. G., Teifel, M., Michaelis, U., & Dellian, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20083 · Cited by 104
Multifunctional drug delivery system for targeting tumor and its acidic microenvironment
Shen, M., Huang, Y., Han, L., Qin, J., Fang, X., Wang, J., & Yang, V. C.-M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.013 · Cited by 103
Youn, C.-K., Kim, M.-H., Cho, H.-J., Kim, H.-B., Chang, I. Y., Chung, M., & You, H. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0348 · Cited by 99
Lee, C. M., & Tannock, I. F. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603010 · Cited by 98
Beh, C. W., Seow, W. Y., Wang, Y., Zhang, Y., Ong, Z. Y., Ee, P. L. R., & Yang, Y. Y. (2008) · Biomacromolecules · doi:10.1021/bm801109g · Cited by 97
Vascular targeting of doxorubicin using cationic liposomes
Wu, J. H., Lee, A., Lu, Y., & Lee, R. J. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.01.003 · Cited by 97
pH-Responsive Nanoparticles for Cancer Drug Delivery
Shen, Y., Tang, H., Radosz, M., Kirk, E. V., & Murdoch, W. J. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-210-6_10 · Cited by 95
Fracasso, P. M., Brady, M. F., Moore, D. H., Walker, J. L., Rose, P. G., Letvak, L. A., Grogan, T. M., & McGuire, W. P. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.2975 · Cited by 95
Schuyer, M., van der Burg, M. E. L., Henzen-Logmans, S. C., Fieret, J. H., Klijn, J. G. M., Look, M. P., Foekens, J. A., Stoter, G., & Berns, E. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2101 · Cited by 95
Shen, J., Sun, H., Xu, P., Yin, Q., Zhang, Z., Wang, S., Yu, H., & Li, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.057 · Cited by 93
Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas
Sinicrope, F. A., Rego, R. L., Okumura, K., Foster, N. R., O’Connell, M. J., Sargent, D. J., & Windschitl, H. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5202 · Cited by 93
Extracellular matrix regulation of drug resistance in small-cell lung cancer
Hodkinson, P. S., MacKinnon, A. C., & Sethi, T. (2007) · International Journal of Radiation Biology · doi:10.1080/09553000701570204 · Cited by 92
Apoptosis: Silencing the death receptors
Tschopp, J., Martinon, F., & Hofmann, K. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80233-4 · Cited by 92
Longo-Sorbello, G. S. A., & Bertino, J. R. (2001) · PubMed · Cited by 92
Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences
Broxterman, H. J., Lankelma, J., & Hoekman, K. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00026-8 · Cited by 91
Cell culture as spheroids: an approach to multicellular resistance.
Desoize, B., Gimonet, D., & Jardiller, J. C. (1998) · PubMed · Cited by 88
Gleixner, K. V., Ferenc, V., Peter, B., Gruze, A., Meyer, R. A., Hadzijusufovic, E., Cerny‐Reiterer, S., Mayerhofer, M., Pickl, W. F., Sillaber, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2181 · Cited by 87
Cheng, J., Gu, Jin, Cheng, S. H., & Wong, W. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s25162 · Cited by 87
Tumor Hypoxia, Drug Resistance, and Metastases
Brown, J. M. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.5.338 · Cited by 84
Loi, M., Marchiò, S., Becherini, P., Paolo, D. D., Soster, M., Curnis, F., Brignole, C., Pagnan, G., Perri, P., & Caffa, I. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.015 · Cited by 83
The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2)
Hardwick, L. J. A., Velamakanni, S., & van Veen, H. W. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707218 · Cited by 82
Bates, S. E., Kang, M. H., Meadows, B., Bakke, S., Choyke, P. L., Merino, M. J., Goldspiel, B. R., Chico, I. M., Smith, T., Chen, C. C., et al. (2001) · Cancer · Cited by 80
Ueda, K., Kawashima, H., Ohtani, S., Deng, W., Ravoori, M. K., Bankson, J. A., Gao, B., Girard, L., Minna, J. D., Roth, J. A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1483 · Cited by 76
Cited by
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Self-citationMechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review
Kanamala, M., Wilson, W. R., Yang, M., Palmer, B. D., & Wu, Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.061 · Cited by 1,004
Polymeric micelles in cancer therapy: State of the art
Ghosh, B., & Biswas, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.016 · Cited by 546
Recent Advances in the Application of Vitamin E TPGS for Drug Delivery
Yang, C., Wu, T., Qi, Y., & Zhang, Z. (2018) · Theranostics · doi:10.7150/thno.22711 · Cited by 402
Nanoparticles modified by polydopamine: Working as “drug” carriers
Jin, A., Wang, Y., Lin, K., & Jiang, L. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.04.003 · Cited by 392
Metadata
- Authors
- Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 65
- Issue
- 13-14
- Pages
- 1748-1762
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2046542140
- Cited by
- 333
- References
- 232
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.